“The board approved the buyback of 3.43 million equity shares of the Company at a price of Rs 350 per equity share for an aggregate amount not exceeding Rs 1,200 million from the equity shareholders of the Company on a proportionate basis through the "Tender Offer" route,” FDC said in a regulatory filing.
As of December 2017, the promoters held 68.89% stake in FDC. Individual shareholder have 14.16% stake, followed by foreign institutional investors (9.37%) and mutual funds (3.67%).
Meanwhile, the pharmaceuticals company reported a strong 94% jump in net profit at Rs 427 million in December 2017 quarter against Rs 220 million in the corresponding quarter of previous year. Operational revenue grew 13% to Rs 2,488 million from Rs 2,201 million in previous year quarter.
At 09:55 AM; the stock was trading 6% higher at Rs 269 on BSE, as compared to 0.94% rise in the S&P BSE Sensex. A combined 253,257 shares changed hands on the counter on BSE and NSE.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in